Abstract: A liquid-sample component analysis method includes a dripping step of dripping a liquid sample onto a flat horizontal surface, a drying step of drying a liquid droplet of the liquid sample formed on the horizontal surface while keeping the liquid droplet still so as to obtain a plurality of concentrically-arranged ring-shaped deposits formed on the horizontal surface and composed of components having different particle diameters, and a measuring step of measuring a vibrational spectrum in each region including only one of the deposits so as to individually acquire vibrational spectra of the plurality of deposits.

Abstract: Examples are described including measurement systems for conducting competition assays. A first chamber of an assay device may be loaded with a sample containing a target antigen. The target antigen in the sample may be allowed to bind to antibody-coated beads in the first chamber. A control layer separating the first chamber from a second chamber may then be opened to allow a labeling agent loaded in a first portion of the second chamber to bind to any unoccupied sites on the antibodies. A centrifugal force may then be applied to transport the beads through a density media to a detection region for measurement by a detection unit.

Abstract: According to an aspect, a server receives first and second transient (changing with time) locations of an entity, the first transient location being associated with a time instance until which the entity is physically present at the first transient location. The server accordingly provides the first transient location as the physical location of the entity prior to the time instance, and the second transient location as the physical location after the time instance. According to another aspect, a client device identifies that a search text (received from a user) is directed to searching for physical locations in view of the search text including an affix. The client device then parses the search text to determine an identifier, sends a location request containing the identifier, receives a response containing a transient location associated with the identifier, and then provides the transient location to the user as the response to the search.

Abstract: An apparatus for testing a fluid sample including a sample receiving member having an opening for receiving a fluid sample, wherein the sample receiving member comprises a sample collection chamber; a sample retention member, in fluid communication with the sample collection chamber, to retain a portion of the fluid sample; and at least one test strip, in fluid communication with the sample collection chamber, to indicate the presence or absence of at least one analyte in the fluid sample.

Abstract: Methods, systems and kits to detect and/or quantify lupus and disease progression in a subject having, or at risk of having, lupus are disclosed.

Abstract: Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.

Abstract: The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.

Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.

Abstract: There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic protein Mb3645c (SEQ ID NO: 1) or an epitope from a polypeptide having at least 76% identity with SEQ ID NO: 1.

Abstract: Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection.

Abstract: A method of determining an infection type in a subject is disclosed. The method comprises measuring the concentration of a first determinant selected from the group consisting of the determinants which are set forth in Table 1 and a second determinant selected from the group of the determinants which are set forth in Table 2 in a subject derived sample, wherein the concentration is indicative of the infection type.

Abstract: The present invention encompasses a method for detecting a target comprising a repeating epitope.

Abstract: Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.

Abstract: The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.

Abstract: The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) polypeptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided.

Abstract: A method for capturing rare cells in blood allows for the preparation of a sample containing the capture of rare cells in blood suitable for a downstream. A method for capturing rare cells in blood includes isolating rare cells in blood from blood, the method including a step of removing white blood cells from the blood before blood filtration using a filter.

Abstract: A method for metastasis diagnosis, including adhering a plurality of Human Umbilical Vein Endothelial Cells (HUVECs) on an array of electrodes patterned on a substrate to cover the array of electrodes by HUVECs, measuring an initial electrical signal from each electrode of the array of electrodes, introducing a metastatic-suspicious sample onto the substrate and measuring a set of time-lapse electrical signals from the array of electrodes. Each electrode has an On/Off two-state, including an On state for an entirely-covered electrode by a HUVEC and an Off state for a partially-covered electrode by a HUVEC. Diagnosing metastasis responsive to detecting a state change from On to Off for at least one electrode of the array of electrodes.

Abstract: Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and CD146 composition in the adjacent tissue. ER+ breast cancers contain two CAF subtypes defined by CD146 expression. CD146neg CAFs suppress ER expression in ER+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch ER proliferation dependency toward EGFR dependency and decrease tumor cell sensitivity to antiendocrine therapy. Conversely, the presence of CD146Ppos CAFs enhances ER expression in ER+ breast cancer cells and sustains ER-dependent proliferation and sensitivity to tamoxifen. Co-cultures of CD146pos CAFs with tamoxifen-resistant breast cancer cells restores sensitivity to tamoxifen. Gene expression profiles of patient breast tumors with predominantly CD146neg CAFs correlate with inferior clinical response to tamoxifen and worse patient outcomes. CAF composition contributes to treatment response and patient outcomes in ER+ breast cancer, and provide a target for drug development.

Abstract: This invention provides methods, reagents, and diagnostic and prognostic markers useful for minimally invasive identification, diagnosis, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.

Abstract: Presented herein are compositions, methods, and kits for determining whether a pulmonary nodule is cancer and/or is not cancer.

Abstract: USP14 is a biomarker for recurrent disease and inhibition of USP14 is of therapeutic benefit for women with endometrial or ovarian cancer.

Abstract: The present invention relates to an antibody that specifically binds to a mutant calreticulin protein, wherein the variable region of the heavy chain of said antibody comprises a CDR-H3 region having an amino acid sequence as depicted in SEQ ID NO.: 3, or a CDR sequence having 75% or more amino acid identity to said CDR; or wherein the variable region of the heavy chain of said antibody comprises a CDR-H3 region having an amino acid sequence as depicted in SEQ ID NO.: 6, or a CDR sequence having 75% or more amino acid identity to said CDR. Hybridoma 8B2-H6-10.7 deposited under accession number DSM ACC3249 with the depositary institute DSMZ on Sep. 12, 2014 as well as antibodies obtainable therefrom are subject of the present invention. The antibodies provided herein can be used in the diagnosis of or therapeutic intervention in myeloid malignancies.

Abstract: Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e.g., metastatic breast cancer, through the determination of Lamellipodin protein or gene expression levels in the subject.

Abstract: A compound of formula (I) as described herein and methods and uses thereof as probes in the mass tagging of biosensors or biologically active materials for use in mass cytometry analysis of tissue samples such as in the detection, labelling and quantification of oxygen-deprived cells by using, for example, tellurophene-tagged 2-nitroimidazole.

Abstract: Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.

Abstract: A reaction system comprises at least one additive and at least one reaction base-plane for augmenting chemical reaction, photoelectrochemical reaction, photochemical reaction or electrochemical reaction. The reaction system further comprises at least one reaction substrate carried out to the chemical reaction, the photoelectrochemical reaction, the photochemical reaction or the electrochemical reaction with the at least one additive and the at least one reaction base-plane. The at least one additive is a kind of reaction enhancer added in the reaction system to improve, augment or accumulate the effeteness of at least one reaction result.

Abstract: Systems comprising a nanocrystal and a luminescent chromophore are disclosed herein. The luminescent chromophore can emit energy having a first wavelength. The luminescent chromophore is configured to transfer the emitted energy having a first wavelength to the nanocrystal. The luminescent chromophore can be linked to the nanocrystal via a covalent bond. Absorption of the energy having first wavelength by the nanocrystal can activate the nanocrystal and result in an increase in quantum yield. In some embodiments, the nanocrystal can include silicon, germanium, carbon, or combinations thereof. In some examples, the luminescent chromophore can be pyrene. The luminescent chromophore and the silicon containing nanocrystal can be in a ratio of about 1:1 to 100:1 in the nanocrystal system. Methods of making and using the system are also disclosed.

Abstract: The present invention relates generally methods and kits for detecting binding interactions, in particular protein-protein interactions, and particularly to high throughput methods for labelling, analysing, detecting and measuring protein-protein interactions.

Abstract: Embodiments of a computer system, a method, and a computer-program product (e.g., software) for analyzing tandem-mass-spectrometry data are described. Using this analysis technique, unanticipated chemical modifications to peptides associated with proteins can be identified. In particular, a modification called a wild-card modification is used to identify the most likely chemical modifications in the peptides. A wild-card modification allows the addition of any mass, typically any integer atomic mass within a range, to any one amino acid residue within a candidate peptide.

Abstract: The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide in a test sample.

Abstract: The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Abstract: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Abstract: This invention relates to a diagnostic test measuring circulating HU proteins or gene transcripts in a blood sample to assess arrhythmic risk in heart failure patients. The invention addresses this need and features a diagnostic/prognostic test for measuring circulating HU levels in a sample to assess arrhythmic risk in heart failure patients, alternatively, to determine the risk of SCD. The methods described herein represent a non-invasive (or minimally invasive) test assay. The methods described herein may also include computing a level of an SCN5A variant, or cardiac transcription factors MESP1 (mesoderm posterior posterior protein 1), or MEF2C (myocyte enhancer factor-2), or any combination thereof.

Abstract: The invention relates to a method for differentiating ischemic stroke from hemorrhagic stroke in a patient and to a method for selecting a patient suffering stroke for a therapy with an antithrombotic agent or with an agent capable of reducing blood pressure based on the determination of the level of GFAP in a sample of said patient in combination with one or more markers selected from the group consisting of NEF3, ?-synuclein, CARNS1 and RBP4, or based on determining the level of RBP4 in a sample of said patient. Furthermore, the invention relates to a kit comprising a reagent for detecting the level of a marker selected from GFAP NEF3, ?-synuclein, CARNS1, RBP4 or a combination thereof and to the use of the said kit in the methods of the invention.

Abstract: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27.

Abstract: Methods and kits for determining, predicting, or diagnosing pulmonary artery hypertension (PAH) and for determining the efficacy of PAH therapy using biomarkers are provided.

Abstract: Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.

Abstract: Described herein are apparatus and methods for detecting substances of abuse or other analytes in liquids. For example, the apparatus and methods described herein can be used for real-time detection of analytes, such as substances of abuse. The methods comprise providing a detection area comprising a chromatographic membrane capable of receiving the liquid and allowing for migration of the liquid, the chromatographic membrane comprising an anti-analyte antibody-particle conjugate, an analyte-conjugate protein at a test line; exposing at least the first location of the apparatus to the liquid; and determining whether an interaction between the analyte-conjugate protein and the liquid occurs to detect the presence of the analyte. The chromatographic membrane may further comprise an anti-species antibody at a control line.

Abstract: The present teachings provide apparatuses and methods for automated handling of samples, e.g., biological or chemical samples. The apparatuses and the methods of the present teachings allow automated performance of various sample manipulation steps without manual intervention. In a preferred embodiment, the present teachings provide apparatuses and methods for automated enrichment of templated beads produced by PCR.

Abstract: The present invention is directed towards an apparatus and methods for a precise, fast and easy to use manipulation of beads. This method is particularly useful to carry out separation between the beads and the remaining supernants present in the fluid, maximizing the collection and purification efficiencies in tips for liquid handling.

Abstract: The present invention lies in the field of automated analyzers and relates to an automated warning system for potentially erroneous measurement results, which may be caused by the loss of a liquid container during a transport process.

Abstract: The invention relates to an arrangement (10) for preparing a plurality of samples for an analytical method, comprising a carousel (14) with a solid housing (12) and moveable receiving parts (16) for the sample containers (18); a control for controlling the receiving parts (16) in the carousel (14); and a sample receiving device (24) for providing the sample to be analysed; one or more stations (24, 26, 28, 30, 32) for preparing samples are provided on the carousel (14), the receiving parts (16) for the sample containers (18) of the carousel (14) can be positioned on said stations; a centrifuge (22) with pairs of opposite lying receiving parts (42) provided for the sample containers (18), and said receiving parts (42) are arranged such that they can move on the centrifuge (22) and the movements can be controlled in such a manner that the sample holder (18) can be transferred between a receiving part (16) in the carousel (14) and a receiving part (42) in the centrifuge (22).

Abstract: A high-throughput automatic analyzer integrates a biochemical analysis section and a blood coagulation analysis section. The analyzer is capable of achieving a reduction in size, system cost, and lifecycle cost. The automatic analyzer includes: a reaction disk; a first reagent dispensing mechanism that dispenses a reagent to reaction cells on the reaction disk; a photometer that irradiates a reaction solution in the reaction cell with light; a reaction cell cleaning mechanism; a reaction vessel supply unit that supplies a disposable reaction vessel for mixing and reacting a sample and a reagent with each other; a second reagent dispensing mechanism that dispenses a reagent to the disposable reaction vessel; a blood coagulation time measuring section that irradiates a reaction solution in the disposable reaction vessel with light to detect transmitted or scattered light; and a sample dispensing mechanism that dispenses a sample to the reaction cell and the disposable reaction vessel.

Abstract: Aspects of the present disclosure include sample analysis methods and systems. According to certain embodiments, provided are methods of analyzing samples in an automated sample analysis system. The methods include introducing samples and sample preparation cartridges into the system, isolating and purifying an analyte (e.g., nucleic acids and/or proteins) present in the samples at a sample preparation station, and performing analyte detection assays in assay mixtures that include the purified analyte. Also provided are automated sample analysis systems that find use, e.g., in performing the methods of the present disclosure. In certain aspects, the methods and systems provide for continuous operator access during replenishment or removal of one or any combination of samples, bulk fluids, reagents, commodities, waste, and/or the like.

Abstract: A method for determining the presence or absence of disposable pipette tips in pipette tip carriers on the work area of a laboratory workstation. Each of the pipette tip carriers has a support panel with receiving holes into each of which a disposable pipette tip can be inserted. The laboratory workstation for carrying out the method has a robot arm with at least one pipette which is designed to receive and dispose of disposable pipette tips. The laboratory workstation has a digital camera which is arranged on a support device and is operatively connected to an analyzing unit. The work area of the laboratory workstation can be completely imaged in at least one first direction using the digital camera.

Abstract: A wheel hub, a pulsar ring, and a magnetic sensor are provided. The wheel hub supports an axle. A brake disc is secured to the wheel hub. The pulsar ring is secured to the wheel hub. The magnetic sensor is configured to detect a passing of a pulsar hole disposed on the pulsar ring. The wheel hub forms a cylindrical outer peripheral surface as an outer peripheral side spigot portion. The brake disc includes a disc-side spigot portion in contact with the cylindrical outer peripheral surface. The pulsar ring includes a ring-side spigot portion in contact with the cylindrical outer peripheral surface. The brake disc and the pulsar ring are co-clamped and secured to a hub-side flange formed at the wheel hub.

Abstract: The present disclosure provides an ultrasonic wind measurement device and an ultrasonic wind measurement method, so as to measure a wind speed and a wind direction in an environment using transmission characteristics of an ultrasonic wave.

Abstract: Apparatus and associated methods relate to generating a frequency spectrum weighting function for use in estimating a rotational frequency of the rotating member. The estimation of the rotational frequency is based on vibrations sensed by an accelerometer remotely located from a rotating member. The frequency spectrum weighting function is generated by a supervised learning method. The method includes receiving a set of test vectors. The test vectors include a rotational frequency value of the rotating member and a vibrational frequency spectrum corresponding to vibrations propagated to the accelerometer. The vibrations include vibrations caused by the rotating member rotating at the rotational frequency. The method includes calculating a test weighting function, and then weighting the vibrational frequency spectra by the test weighting function.

Abstract: Apparatus and associated methods relate to maximizing a signal to noise ratio of an accelerometer by inhibiting signals arising from movements of a proofmass in directions perpendicular to a direction of intended sensitivity. The direction of intended sensitivity of the accelerometer is along an axis of the proofmass. The accelerometer is rendered substantially insensitive to lateral accelerations of the proofmass by making the accelerometer axially symmetric. Two axially-asymmetric acceleration sensing devices are axially engaged in such a manner as to render the coupled sensing devices substantially axially-symmetric. In some embodiments, each acceleration sensor has an axially-thin membrane portion extending from a proofmass portion. The two acceleration sensors can be engaged in an antiparallel fashion at projecting ends of the proofmass portions.

Abstract: An acceleration sensor, a display device, a detecting system and a detecting method are provided; the acceleration sensor includes two electrodes arranged opposite to and insulated from each other, and a cavity arranged between the two electrodes; a liquid layer is arranged in the cavity, and the liquid layer occupies a portion of internal space of the cavity. A display device integrated with the acceleration sensor has advantages such as high degree of integration, compact structure and low production cost and so on.